This site is intended for healthcare professionals
Responding to unmet needs for metastatic castration-resistant prostate cancer
Responding to unmet needs for metastatic castration-resistant prostate cancer

Expert opinions on mCRPC management

Read time: 20 mins
Last updated:10th Mar 2023
Published:15th Feb 2023

In this part of the Learning Zone, Professor Axel Merseburger (Chairman of the Department of Urology, University Hospital Schleswig-Holstein, Germany) and Professor Karim Fizazi (Institut Gustave Roussy; Université Paris-Saclay, France) present video content on metastatic castration-resistant prostate cancer (mCRPC) management that is relevant, educational, trustworthy and engaging. The video sections are:

  • Unmet needs in mCRPC
  • Challenges applying guidelines for mCRPC
  • Improvements in management of mCRPC

Meet the Learning Zone experts below.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Challenges applying guidelines for metastatic castration-resistant prostate cancer

One international real-world study found that treatment patterns for metastatic castration-resistant cancer (mCRPC) were consistent with country guideline recommendations for mCRPC, and accorded with the treatments that were reimbursed8.

Once a pharmaceutical treatment for mCRPC is approved, there is an expectation for regular and clear updates of international guidelines. However, healthcare professionals and patients can struggle to be informed, or understand, guidelines for mCRPC9,10.

The videos in this section, presented by Professor Axel Merseburger (Chairman of the Department of Urology, University Hospital Schleswig-Holstein, Germany) and Professor Karim Fizazi (Institut Gustave Roussy; Université Paris-Saclay, France), describe the main clinical practice guideline recommendations for mCRPC, and the recommendations that, for whatever reason, are challenging to implement in clinical practice. Professor Merseburger speculates on why uptake of some guideline recommendations remains low.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Improvements in management of metastatic castration-resistant prostate cancer

In this section, Professor Karim Fizazi (Institut Gustave Roussy; Université Paris-Saclay, France) reviews recent improvements in management of metastatic castration-resistant prostate cancer (mCRPC). He states why mCRPC is clinically important, describes improvements that have made a difference to patients with mCRPC, and if knowledge of treatment mechanism of action can improve management of this disease.

In the final video, Professor Merseburger (Chairman of the Department of Urology, University Hospital Schleswig-Holstein, Germany) observes that treating mCRPC requires weighing several, interacting clinical factors, not one. Continue below to view this free educational content.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Welcome: